Label: LEVO-T- levothyroxine sodium tablet
-
NDC Code(s):
55466-104-11,
55466-104-19,
55466-105-11,
55466-105-19, view more55466-106-11, 55466-106-19, 55466-107-11, 55466-107-19, 55466-108-11, 55466-108-19, 55466-109-11, 55466-109-19, 55466-110-11, 55466-110-19, 55466-111-11, 55466-111-19, 55466-112-11, 55466-112-19, 55466-113-11, 55466-113-19, 55466-114-11, 55466-114-19, 55466-115-11, 55466-115-19
- Packager: Neolpharma, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: New Drug Application
Drug Label Information
Updated March 26, 2024
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
-
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use LEVO-T® safely and effectively. See full prescribing information for LEVO-T.
LEVO-T® (levothyroxine sodium) tablets, for oral use
Initial U.S. Approval:2002WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
See full prescribing information for complete boxed warning
- Thyroid hormones, including LEVO-T, should not be used for the treatment of obesity or for weight loss.
- Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity (6, 10).
INDICATIONS AND USAGE
LEVO-T is L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: (1)
- Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1)
- Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1)
(1)
Limitations of Use (1)
- Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients
- Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis
DOSAGE AND ADMINISTRATION
- Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. (2.1)
- Administer at least 4 hours before or after drugs that are known to interfere with absorption. (2.1)
- Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. (2.1)
- Advise patients to stop biotin and biotin-containing supplements at least 2 days before assessing TSH and/or T4 levels. (2.2)
- Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4-6 weeks. (2.2)
- See full prescribing information for dosing in specific patient populations. (2.3)
- Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. (2.4)
(2)
DOSAGE FORMS AND STRENGTHS
Tablets: 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, and 300 mcg (3) (3)
CONTRAINDICATIONS
- Uncorrected adrenal insufficiency. (4)
WARNINGS AND PRECAUTIONS
- Serious risks related to overtreatment or undertreatment with LEVO-T: Titrate the dose of LEVO-T carefully and monitor response to titration. (5.1)
- Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate LEVO-T at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation. (2.3, 5.2, 8.5)
- Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma. (5.3)
- Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of LEVO-T treatment. (5.4)
- Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy. (5.5)
- Decreased bone mineral density associated with thyroid hormone over- replacement: Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose. (5.6)
ADVERSE REACTIONS
Adverse reactions associated with LEVO-T therapy are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash. (6) (6)
(6)
To report SUSPECTED ADVERSE REACTIONS, contact Neolpharma, Inc. at 1-844-200-4163 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (6)
(6)
DRUG INTERACTIONS
See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to LEVO-T. ( 7)
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 3/2024
-
Table of Contents
FULL PRESCRIBING INFORMATION: CONTENTS*
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
1 INDICATIONS AND USAGE
Hypothyroidism
Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression
2 DOSAGE AND ADMINISTRATION
2.1 Important Administration Information
2.2 Important Considerations for Dosing
2.3 Recommended Dosage and Titration
2.4 Monitoring TSH and/or Thyroxine (T4) Levels
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Serious Risks Related to Overtreatment or Undertreatment with LEVO-T
5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease
5.3 Myxedema Coma
5.4 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency
5.5 Worsening of Diabetic Control
5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement
6 ADVERSE REACTIONS
Adverse Reactions in Pediatric Patients
Hypersensitivity Reactions
7 DRUG INTERACTIONS
7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics
7.2 Antidiabetic Therapy
7.3 Oral Anticoagulants
7.4 Digitalis Glycosides
7.5 Antidepressant Therapy
7.6 Ketamine
7.7 Sympathomimetics
7.8 Tyrosine-Kinase Inhibitors
7.9 Drug-Food Interactions
7.10 Drug-Laboratory Test Interactions
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
16 HOW SUPPLIED/STORAGE AND HANDLING
Storage and Handling
17 PATIENT COUNSELING INFORMATION
Dosing and Administration
Important Information
Adverse Reactions
- *
- Sections or subsections omitted from the full prescribing information are not listed.
-
BOXED WARNING
(What is this?)
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
Thyroid hormones, including LEVO-T, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.
In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.
Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)].
-
1 INDICATIONS AND USAGE
Hypothyroidism
LEVO-T is indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression
LEVO-T is indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Limitations of Use
- LEVO-T is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with LEVO-T may induce hyperthyroidism [see Warnings and Precautions (5.1)].
- LEVO-T is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
-
2 DOSAGE AND ADMINISTRATION
2.1 Important Administration Information
Take LEVO-T with a full glass of water as the tablet may rapidly disintegrate.
Administer LEVO-T as a single daily dose, on an empty stomach, one-half to one hour before breakfast.
Administer LEVO-T at least 4 hours before or after drugs known to interfere with LEVO-T absorption [see Drug Interactions (7.1)].
Evaluate the need for dosage adjustments when regularly administering within one hour of certain foods that may affect LEVO-T absorption [see Dosage and Administration (2.2 and 2.3), Drug Interactions (7.9) and Clinical Pharmacology (12.3)].
Administer LEVO-T to pediatric patients who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 to 10 mL) of water and immediately administering the suspension by spoon or dropper. Ensure the patient ingests the full amount of the suspension. Do not store the suspension. Do not administer in foods that decrease absorption of LEVO-T, such as soybean-based infant formula [see Drug Interactions (7.9)].
2.2 Important Considerations for Dosing
The dosage of LEVO-T for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated [see Dosage and Administration (2.3), Warnings and Precautions (5), and Drug Interactions (7)]. Dosing must be individualized to account for these factors and dosage adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.4)].
For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal [see Dosage and Administration (2.3)].
For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of LEVO-T dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate LEVO-T dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range [see Dosage and Administration (2.3)].
Inquire whether patients are taking biotin or biotin-containing supplements. If so, advise them to stop biotin supplementation at least 2 days before assessing TSH and/or T4 levels [see Dosage and Administration (2.4) and Drug Interactions (7.10)].
The peak therapeutic effect of a given dose of LEVO-T may not be attained for 4 to 6 weeks.
2.3 Recommended Dosage and Titration
Primary, Secondary, and Tertiary Hypothyroidism in Adults
The recommended starting daily dosage of LEVO-T in adults with primary, secondary, or tertiary hypothyroidism is based on age and comorbid cardiac conditions, as described in Table 1. For patients at risk of atrial fibrillation or patients with underlying cardiac disease, start with a lower dosage and titrate the dosage more slowly to avoid exacerbation of cardiac symptoms. Dosage titration is based on serum TSH or free-T4 [see Dosage and Administration (2.2)].
Table 1. LEVO-T Dosing Guidelines for Hypothyroidism in Adults*
Patient Population Starting Dosage Dosage Titration Based on Serum TSH or Free-T4 Adults diagnosed with hypothyroidism Full replacement dose is 1.6 mcg/kg/day. Some patients require a lower starting dose. Titrate dosage by 12.5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid. Adults at risk for atrial fibrillation or with underlying cardiac disease Lower starting dose (less than 1.6 mcg/kg/day) Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid. Geriatric patients Lower starting dose (less than 1.6 mcg/kg/day) *Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors [see Dosage and Administration (2.1) and Drug Interactions (7)].
Primary, Secondary, and Tertiary Hypothyroidism in Pediatric Patients
The recommended starting daily dosage of LEVO-T in pediatric patients with primary, secondary, or tertiary hypothyroidism is based on body weight and changes with age as described in Table 2. Titrate the dosage (every 2 weeks) as needed based on serum TSH or free-T4 until the patient is euthyroid [see Dosage and Administration (2.2)].
Table 2. LEVO-T Dosing Guidelines for Hypothyroidism in Pediatric Patients
Age Starting Daily Dosage Per Kg Body Weight* 0-3 months 10-15 mcg/kg/day 3-6 months 8-10 mcg/kg/day 6-12 months 6-8 mcg/kg/day 1-5 years 5-6 mcg/kg/day 6-12 years 4-5 mcg/kg/day Greater than 12 years but growth and
puberty incomplete2-3 mcg/kg/day Growth and puberty complete 1.6 mcg/kg/day *Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4)].
*Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4)].
Pediatric Patients from Birth to 3 Months of Age at Risk for Cardiac Failure
Start at a lower starting dosage and increase the dosage every 4 to 6 weeks as needed based on clinical and laboratory response.
Pediatric Patients at Risk for Hyperactivity
To minimize the risk of hyperactivity, start at one-fourth the recommended full replacement dosage, and increase on a weekly basis by one-fourth the full recommended replacement dosage until the full recommended replacement dosage is reached.
Hypothyroidism in Pregnant Patients
For pregnant patients with pre-existing hypothyroidism, measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In pregnant patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. The recommended daily dosage of LEVO-T in pregnant patients is described in Table 3.
Table 3. LEVO-T Dosing Guidelines for Hypothyroidism in Pregnant Patients
Patient Population Starting Dosage Dose Adjustment and Titration Pre-existing primary hypothyroidism with serum TSH above normal trimester-specific range Pre-pregnancy dosage may increase during pregnancy Increase LEVO-T dosage by 12.5 to 25 mcg per day. Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range.
Reduce LEVO-T dosage to pre-pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum.New onset hypothyroidism
(TSH ≥ 10 mIU per liter)1.6 mcg/kg/day Monitor serum TSH every 4 weeks and adjust LEVO-T dosage until serum TSH is within normal trimester specific range. New onset hypothyroidism (TSH < 10 mIU per liter) 1.0 mcg/kg/day 2.4 Monitoring TSH and/or Thyroxine (T4) Levels
Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation.
Biotin supplementation may interfere with immunoassays for TSH, T4, and T3, resulting in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days before assessing TSH and/or T4 levels [see Drug Interactions (7.10)].
Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of LEVO-T may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.
Adults
In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dose. In patients on a stable and appropriate replacement dosage, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status.
Pediatric Patients
In patients with hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in pediatric patients as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dosage stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals.
The general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of LEVO-T therapy and/or of the serum TSH to decrease below 20 IU per liter within 4 weeks may indicate the patient is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of LEVO-T [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].
-
3 DOSAGE FORMS AND STRENGTHS
LEVO-T tablets are available as follows (Table 4):
Table 4. LEVO-T Tablet Strengths and Identifying Features
Tablet Strength Tablet Color/Shape Tablet Markings 25 mcg Orange/Caplet "25" and "GG/331" 50 mcg White/ Caplet "50" and "GG/332" 75 mcg Violet/ Caplet "75" and "GG/333" 88 mcg Olive Green/ Caplet "88" and "GG/334" 100 mcg Yellow/ Caplet "100" and "GG/335" 112 mcg Rose/ Caplet "112" and "GG/336" 125 mcg Brown/ Caplet "125" and "GG/337" 137 mcg Turquoise/ Caplet "137" and "GG/330" 150 mcg Blue/ Caplet "150" and "GG/338" 175 mcg Lilac/ Caplet "175" and "GG/339" 200 mcg Pink/ Caplet "200" and "GG/340" 300 mcg Green/ Caplet "300" and "GG/341" - 4 CONTRAINDICATIONS
-
5 WARNINGS AND PRECAUTIONS
5.1 Serious Risks Related to Overtreatment or Undertreatment with LEVO-T
LEVO-T has a narrow therapeutic index. Overtreatment or undertreatment with LEVO-T may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, gastrointestinal function, and glucose and lipid metabolism in adult or pediatric patients.
In pediatric patients with congenital and acquired hypothyroidism, undertreatment may adversely affect cognitive development and linear growth, and overtreatment is associated with craniosynostosis and acceleration of bone age [see Use in Specific Populations (8.4)].
Titrate the dose of LEVO-T carefully and monitor response to titration to avoid these effects [see Dosage and Administration (2.4)]. Consider the potential for food or drug interactions and adjust the administration or dosage of LEVO-T as needed [see Dosage and Administration (2.1), Drug Interactions (7.1), and Clinical Pharmacology (12.3)].
5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease
Overtreatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate LEVO-T therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see Dosage and Administration (2.3), and Use in Specific Populations (8.5)].
Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive LEVO-T therapy. Monitor patients receiving concomitant LEVO-T and sympathomimetic agents for signs and symptoms of coronary insufficiency.
If cardiac symptoms develop or worsen, reduce the LEVO-T dose or withhold for one week and restart at a lower dose.
5.3 Myxedema Coma
Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.
5.4 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency
Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with LEVO-T [see Contraindications (4)].
5.5 Worsening of Diabetic Control
Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing LEVO-T [see Drug Interactions (7.2)].
5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement
Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of LEVO-T that achieves the desired clinical and biochemical response to mitigate this risk.
-
6 ADVERSE REACTIONS
Adverse reactions associated with LEVO-T therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions (5), and Overdosage (10)]. They include the following:
- General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
- Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
- Musculoskeletal: tremors, muscle weakness, muscle spasm
- Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
- Respiratory: dyspnea
- Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests
- Dermatologic: hair loss, flushing, rash
- Endocrine: decreased bone mineral density
- Reproductive: menstrual irregularities, impaired fertility
Seizures have been reported rarely with the institution of levothyroxine therapy.
Adverse Reactions in Pediatric Patients
Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants who have not undergone complete closure of the fontanelles, and in premature closure of the epiphyses in pediatric patients still experiencing growth with resultant compromised adult height.
Hypersensitivity Reactions
Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.
-
7 DRUG INTERACTIONS
7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics
Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to LEVO-T (Tables 5 to 8).
Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of LEVO-T by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Drug or Drug Class Effect Phosphate Binders
(e.g., calcium carbonate, ferrous sulfate, sevelamer, lanthanum)Phosphate binders may bind to levothyroxine. Administer LEVO-T at least 4 hours apart from these agents. Orlistat Monitor patients treated concomitantly with orlistat and LEVO-T for changes in thyroid function. Bile Acid Sequestrants (e.g., colesevelam, cholestyramine, colestipol)
Ion Exchange Resins
(e.g., Kayexalate)Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer LEVO-T at least 4 hours prior to these drugs or monitor TSH levels. Proton Pump Inhibitors Sucralfate
Antacids
(e.g., aluminum & magnesium hydroxides, simethicone)Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately. Table 6. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate
Estrogen-containing oral contraceptives
Estrogens (oral)
Heroin / Methadone
5-Fluorouracil
Mitotane
TamoxifenThese drugs may increase serum thyroxine-binding globulin (TBG) concentration. Androgens / Anabolic Steroids
Asparaginase
Glucocorticoids
Slow-Release Nicotinic AcidThese drugs may decrease serum TBG concentration. Potential impact (below): Administration of these agents with LEVO-T results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations. Salicylates (> 2 g/day) Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%. Other drugs:
Carbamazepine
Furosemide (> 80 mg IV)
Heparin
Hydantoins
Non-Steroidal Anti-inflammatory Drugs
-FenamatesThese drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters. Table 7. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism) Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased LEVO-T requirements. Drug or Drug Class Effect Phenobarbital Rifampin Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine. Table 8. Drugs That May Decrease Conversion of T4 to T3 Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased. Drug or Drug Class Effect Beta-adrenergic antagonists (e.g., Propranolol > 160 mg/day) In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state. Glucocorticoids (e.g., Dexamethasone ≥ 4 mg/day) Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above). Other drugs: Amiodarone Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients. 7.2 Antidiabetic Therapy
Addition of LEVO-T therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued [see Warnings and Precautions (5.5)].
7.3 Oral Anticoagulants
LEVO-T increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the LEVO-T dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.
7.4 Digitalis Glycosides
LEVO-T may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.
7.5 Antidepressant Therapy
Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and LEVO-T may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. LEVO-T may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on LEVO-T may result in increased LEVO-T requirements.
7.6 Ketamine
Concurrent use of ketamine and LEVO-T may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.
7.7 Sympathomimetics
Concurrent use of sympathomimetics and LEVO-T may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.
7.8 Tyrosine-Kinase Inhibitors
Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.
7.9 Drug-Food Interactions
Consumption of certain foods may affect LEVO-T absorption thereby necessitating adjustments in dosing [see Dosage and Administration (2.1)]. Soybean flour, cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of LEVO-T from the gastrointestinal tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability.
7.10 Drug-Laboratory Test Interactions
Thyroxine-binding Globulin (TBG)
Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free-T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentration. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.
-
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
The clinical experience, including data from postmarketing studies, in pregnant women treated with oral levothyroxine to maintain euthyroid state have not reported increased rates of major birth defects, miscarriages, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since TSH levels may increase during pregnancy, TSH should be monitored and LEVO-T dosage adjusted during pregnancy ( see Clinical Considerations). Animal reproductive studies have not been conducted with levothyroxine sodium. LEVO-T should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations
Disease-Associated Maternal and/or Embryo/Fetal Risk
Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.
Dose Adjustments During Pregnancy and the Postpartum Period
Pregnancy may increase LEVO-T requirements. Serum TSH levels should be monitored and the LEVO-T dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the LEVO-T dosage should return to the pre-pregnancy dose immediately after delivery [see Dosage and Administration (2.3)].
Disease-Associated Maternal and/or Embryo/Fetal Risk
Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.
Dose Adjustments During Pregnancy and the Postpartum Period
Pregnancy may increase LEVO-T requirements. Serum TSH levels should be monitored and the LEVO-T dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the LEVO-T dosage should return to the pre-pregnancy dose immediately after delivery [see Dosage and Administration (2.3)].
Data
Human Data
Levothyroxine is approved for use as a replacement therapy for hypothyroidism. There is a long experience of levothyroxine use in pregnant women, including data from post-marketing studies that have not reported increased rates of fetal malformations, miscarriages or other adverse maternal or fetal outcomes associated with levothyroxine use in pregnant women.
8.2 Lactation
Risk Summary
Published studies report that levothyroxine is present in human milk following the administration of oral levothyroxine. No adverse effects on the breastfed infant have been reported and there is no information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers with low milk supply. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LEVO-T and any potential adverse effects on the breastfed infant from LEVO-T or from the underlying maternal condition.
8.4 Pediatric Use
LEVO-T is indicated in patients from birth to less than 17 years of age:
- As a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
- As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer
Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on cognitive development as well as on overall physical growth and maturation. Therefore, initiate LEVO-T therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients [see Warnings and Precautions (5.1)].
Closely monitor infants during the first 2 weeks of LEVO-T therapy for cardiac overload and arrhythmias.
Congenital Hypothyroidism [See Dosage and Administration (2.3, 2.4)]
Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. Therefore, initiate LEVO-T therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients.
Closely monitor infants during the first 2 weeks of LEVO-T therapy for cardiac overload, arrhythmias, and aspiration from avid suckling.
Closely monitor patients to avoid undertreatment or overtreatment. Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment is associated with craniosynostosis in infants, may adversely affect the tempo of brain maturation, and may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.
Acquired Hypothyroidism in Pediatric Patients
Closely monitor patients to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. Overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.
Treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. In children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height.
8.5 Geriatric Use
Because of the increased prevalence of cardiovascular disease among the elderly, initiate LEVO-T at less than the full replacement dose [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)]. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly.
-
10 OVERDOSAGE
The signs and symptoms of overdosage are those of hyperthyroidism [see Warnings and Precautions (5) and Adverse Reactions (6)]. In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year- old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.
Reduce the LEVO-T dose or discontinue temporarily if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient’s medical status.
For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.
-
11 DESCRIPTION
LEVO-T (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is chemically identical to that produced in the human thyroid gland. Levothyroxine (T4) sodium has an empirical formula of C 15H 10I 4NNaO 4∙xH 2O (where x = 5), molecular weight of 798.86 g/mol (anhydrous), and structural formula as shown:
LEVO-T tablets for oral administration are supplied in the following strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Each LEVO-T tablet contains the inactive ingredients colloidal silicone dioxide, NF; magnesium stearate, NF; microcrystalline cellulose, NF; and sodium starch glycolate, NF. LEVO-T tablets contain no ingredients made from a gluten-containing grain (wheat, barley, or rye). LEVO-T tablets do not contain lactose. Each tablet strength meets USP Dissolution Test 2. Table 9 provides a listing of the color additives by tablet strength:
Table 9. LEVO-T Tablets Color Additives Strength (mcg) Color additive(s) 25 FD&C Yellow No. 6 Aluminum Lake 50 None 75 FD&C Blue No. 2 Aluminum Lake, D&C Red No. 27 Aluminum Lake 88 FD&C Blue No. 1 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake, D&C Red No. 30 Aluminum Lake 100 D&C Yellow No. 10 Aluminum Lake, D&C Red Lake Blend (D&C Red No. 27 Lake and D&C Red No. 30 Lake) 112 D&C Red No. 27 Aluminum Lake, D&C Red No. 30 Aluminum Lake 125 FD&C Yellow No. 6 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake 137 FD&C Blue No. 1 Aluminum Lake 150 FD&C Blue No. 2 Aluminum Lake 175 D&C Red No. 27 Aluminum Lake, D&C Red No. 30 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake 200 D&C Yellow No. 10 Aluminum Lake, D&C Red No. 27 Aluminum Lake 300 D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake -
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.
The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.
12.2 Pharmacodynamics
Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.
12.3 Pharmacokinetics
Absorption
Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the LEVO-T dose is absorbed from the jejunum and upper ileum. The relative bioavailability of LEVO-T tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 99%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption [see Drug Interactions (7)].
Distribution
Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins [see Drug Interactions (7)]. Thyroid hormones do not readily cross the placental barrier [see Use in Specific Populations (8.1)].
Elimination
Metabolism
T4 is slowly eliminated (Table 10). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.
Excretion
Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.
Table 10. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients Hormone Ratio in Thyroglobulin Biologic Potency t 1/2 (days) Protein Binding (%) * Levothyroxine (T4) 10 - 20 1 6-7 **†99.96 Liothyronine (T3) 1 4 ≤ 2 99.5 *Includes TBG, TBPA, and TBA
**3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism - 13 NONCLINICAL TOXICOLOGY
-
16 HOW SUPPLIED/STORAGE AND HANDLING
How Supplied
LEVO-T (levothyroxine sodium, USP) tablets are supplied as follows (Table 11):
Table 11. LEVO-T Tablet Presentations
Strength (mcg) Color/Shape Tablet Markings NDC# for bottles of 90 NDC # for bottles of 1000 25 Orange/Caplet "25" and "GG/331" 55466-104-11 55466-104-19 50 White/ Caplet "50" and "GG/332" 55466-105-11 55466-105-19 75 Violet/ Caplet "75" and "GG/333" 55466-106-11 55466-106-19 88 Olive Green/ Caplet "88" and 'GG/334" 55466-107-11 5466-107-19 100 Yellow/ Caplet "100" and "GG/335" 55466-108-11 55466-108-19 112 Rose/ Caplet "112" and "GG/336" 55466-109-11 55466-109-19 125 Brown/ Caplet "125" and "GG/337" 55466-110-11 55466-110-19 137 Turquoise/ Caplet "137" and "GG/330" 55466-111-11 55466-111-19 150 Blue/ Caplet "150" and "GG/338" 55466-112-11 55466-112-19 175 Lilac/ Caplet "175" and "GG/339" 55466-113-11 55466-113-19 200 Pink/ Caplet "200" and "GG/340" 55466-114-11 55466-114-19 300 Green/ Caplet "300" and "GG/341" 55466-115-11 55466-115-19 -
17 PATIENT COUNSELING INFORMATION
Inform the patient of the following information to aid in the safe and effective use of LEVO-T:
Dosing and Administration
- Instruct patients that LEVO-T should be taken with a full glass of water since the tablet may rapidly disintegrate.
- Instruct patients to take LEVO-T only as directed by their healthcare provider.
- Instruct patients to take LEVO-T as a single dose, preferably on an empty stomach, one-half to one hour before breakfast.
- Inform patients that agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine. Instruct patients not to take LEVO-T tablets within 4 hours of these agents.
- Instruct patients to notify their healthcare provider if they are pregnant or breastfeeding or are thinking of becoming pregnant while taking LEVO-T.
Important Information
- Inform patients that it may take several weeks before they notice an improvement in symptoms.
- Inform patients that the levothyroxine in LEVO-T is intended to replace a hormone that is normally produced by the thyroid gland. Generally, replacement therapy is to be taken for life.
- Inform patients that LEVO-T should not be used as a primary or adjunctive therapy in a weight control program.
Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.
- Instruct patients to discontinue biotin or any biotin-containing supplements for at least 2 days before thyroid function testing is conducted.
- Instruct patients to notify their physician of any other medical conditions they may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while they are taking LEVO-T. If they have diabetes, instruct patients to monitor their blood and/or urinary glucose levels as directed by their physician and immediately report any changes to their physician. If patients are taking anticoagulants, their clotting status should be checked frequently.
- Instruct patients to notify their physician or dentist that they are taking LEVO-T prior to any surgery.
Adverse Reactions
- Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.
- Inform patients that partial hair loss may occur rarely during the first few months of LEVO-T therapy, but this is usually temporary.
Manufactured and Distributed by:
Neolpharma, Inc.
Caguas, Puerto Rico 00725
PP10403
- Principal Display Panel
-
INGREDIENTS AND APPEARANCE
LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-114 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 200 ug Inactive Ingredients Ingredient Name Strength D&C RED NO. 27 ALUMINUM LAKE (UNII: ZK64F7XSTX)  D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  MAGNESIUM STEARATE (UNII: 70097M6I30)  Product Characteristics Color pink Score no score Shape CAPSULE (caplet) Size 9mm Flavor Imprint Code 200;GG;340 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-114-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-114-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 03/26/2024 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-115 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 300 ug Inactive Ingredients Ingredient Name Strength D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  FD&C BLUE NO. 1--ALUMINUM LAKE (UNII: J9EQA3S2JM)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  MAGNESIUM STEARATE (UNII: 70097M6I30)  Product Characteristics Color green Score no score Shape CAPSULE (caplet) Size 9mm Flavor Imprint Code 300;GG;341 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-115-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-115-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 03/26/2024 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-112 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 150 ug Inactive Ingredients Ingredient Name Strength FD&C BLUE NO. 2--ALUMINUM LAKE (UNII: 4AQJ3LG584)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  MAGNESIUM STEARATE (UNII: 70097M6I30)  Product Characteristics Color blue Score no score Shape CAPSULE (caplet) Size 9mm Flavor Imprint Code 150;GG;338 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-112-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-112-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 03/26/2024 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-113 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 175 ug Inactive Ingredients Ingredient Name Strength D&C RED NO. 27 ALUMINUM LAKE (UNII: ZK64F7XSTX)  D&C RED NO. 30 (UNII: 2S42T2808B)  FD&C BLUE NO. 1--ALUMINUM LAKE (UNII: J9EQA3S2JM)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  MAGNESIUM STEARATE (UNII: 70097M6I30)  Product Characteristics Color purple ((lilac)) Score no score Shape CAPSULE (caplet) Size 9mm Flavor Imprint Code 175;GG;339 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-113-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-113-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 03/26/2024 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-111 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 137 ug Inactive Ingredients Ingredient Name Strength FD&C BLUE NO. 1--ALUMINUM LAKE (UNII: J9EQA3S2JM)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  MAGNESIUM STEARATE (UNII: 70097M6I30)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  Product Characteristics Color turquoise Score no score Shape CAPSULE (Caplet) Size 9mm Flavor Imprint Code 137;GG;330 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-111-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-111-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 03/26/2024 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-110 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 125 ug Inactive Ingredients Ingredient Name Strength FD&C RED NO. 40 (UNII: WZB9127XOA)  FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  FD&C BLUE NO. 1--ALUMINUM LAKE (UNII: J9EQA3S2JM)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  MAGNESIUM STEARATE (UNII: 70097M6I30)  Product Characteristics Color brown Score no score Shape CAPSULE (caplet) Size 9mm Flavor Imprint Code 125;GG;337 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-110-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-110-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 11/29/2018 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-105 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 50 ug Inactive Ingredients Ingredient Name Strength SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  MAGNESIUM STEARATE (UNII: 70097M6I30)  Product Characteristics Color white Score no score Shape CAPSULE (Caplet) Size 9mm Flavor Imprint Code 50;GG;332 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-105-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-105-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 08/07/2018 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-106 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 75 ug Inactive Ingredients Ingredient Name Strength FD&C BLUE NO. 2--ALUMINUM LAKE (UNII: 4AQJ3LG584)  D&C RED NO. 27 ALUMINUM LAKE (UNII: ZK64F7XSTX)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  MAGNESIUM STEARATE (UNII: 70097M6I30)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  Product Characteristics Color purple ((violet)) Score no score Shape CAPSULE (Caplet) Size 9mm Flavor Imprint Code 75;GG;333 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-106-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-106-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 09/05/2018 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-104 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 25 ug Inactive Ingredients Ingredient Name Strength FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  MAGNESIUM STEARATE (UNII: 70097M6I30)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  Product Characteristics Color orange Score no score Shape CAPSULE (caplet) Size 9mm Flavor Imprint Code 25;GG;331 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-104-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-104-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 08/07/2018 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-108 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 100 ug Inactive Ingredients Ingredient Name Strength D&C RED NO. 27 (UNII: 2LRS185U6K)  D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  D&C RED NO. 30 (UNII: 2S42T2808B)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  MAGNESIUM STEARATE (UNII: 70097M6I30)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  Product Characteristics Color yellow Score no score Shape CAPSULE (Caplet) Size 9mm Flavor Imprint Code 100;GG;335 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-108-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-108-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 09/05/2018 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-107 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 88 ug Inactive Ingredients Ingredient Name Strength FD&C BLUE NO. 1--ALUMINUM LAKE (UNII: J9EQA3S2JM)  D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  D&C RED NO. 30 (UNII: 2S42T2808B)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  MAGNESIUM STEARATE (UNII: 70097M6I30)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  Product Characteristics Color green ((olive)) Score no score Shape CAPSULE (caplet) Size 9mm Flavor Imprint Code 88;GG;334 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-107-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-107-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 03/26/2024 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 LEVO-TÂ
levothyroxine sodium tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55466-109 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 112 ug Inactive Ingredients Ingredient Name Strength D&C RED NO. 30 (UNII: 2S42T2808B)  D&C RED NO. 27 ALUMINUM LAKE (UNII: ZK64F7XSTX)  MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  MAGNESIUM STEARATE (UNII: 70097M6I30)  SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  Product Characteristics Color pink ((Rose)) Score no score Shape CAPSULE (caplet) Size 9mm Flavor Imprint Code 112;GG;336 Contains     Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55466-109-11 90 in 1 BOTTLE; Type 0: Not a Combination Product 10/29/2015 2 NDC:55466-109-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 03/26/2024 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021342 10/29/2015 Labeler - Neolpharma, Inc. (078709787) Registrant - Neolpharma, Inc. (078709787) Establishment Name Address ID/FEI Business Operations Neolpharma, Inc. 078709787 pack(55466-104, 55466-105, 55466-106, 55466-108, 55466-110, 55466-107, 55466-109, 55466-111, 55466-112, 55466-113, 55466-114, 55466-115) , analysis(55466-104, 55466-105, 55466-106, 55466-108, 55466-110, 55466-107, 55466-109, 55466-111, 55466-112, 55466-113, 55466-114, 55466-115) , manufacture(55466-105, 55466-106, 55466-108, 55466-110, 55466-104, 55466-107, 55466-109, 55466-111, 55466-112, 55466-113, 55466-114, 55466-115) , label(55466-104, 55466-105, 55466-106, 55466-108, 55466-110, 55466-107, 55466-109, 55466-111, 55466-112, 55466-113, 55466-114, 55466-115)
